Core Insights - The company Yongda Pharmaceutical (00512) has announced the completion of the first patient enrollment in the IIa clinical trial for its innovative ophthalmic drug GPN00884, aimed at delaying the progression of myopia in children [1][2] - GPN00884 is a novel eye drop formulation that does not cause pupil dilation or associated side effects, potentially improving patient compliance compared to existing treatments like low-concentration atropine [1] - The IIa trial will enroll over 80 participants aged 6 to 12 years to evaluate the efficacy and safety of GPN00884 in a randomized, double-blind, placebo-controlled setting [1] Group 1 - GPN00884 is designed to address the unmet clinical needs in the treatment of myopia in children, where there is currently a lack of effective and safe medications in the domestic market [1] - The drug has previously completed a successful I phase clinical trial, demonstrating good safety and tolerability in healthy subjects, with linear pharmacokinetic characteristics [2] - The initiation of the IIa clinical trial marks a significant milestone for the company in the ophthalmology sector [2]
远大医药：全球创新眼科药物GPN00884在中国开展的IIa期临床研究完成了首例患者入组